XORTX Therapeutics Inc. (XRTX) Stock Price & Analysis
XORTX Therapeutics Inc. (XRTX) closed at USD 1.42 on Thursday, October 15, 2026, down 8.97% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.56; the Oct 15, 2026 session ranged USD 1.41–1.54 on volume of 91,997 shares. Market capitalization is $2.58M, with a 52-week range of USD 1.36–7.05 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/XRTX.md
Key facts (XRTX)
- Total return with dividends: 1Y -66.6% vs S&P 500 +18.1%; 5Y -99.9% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD —, revenue estimate $0K.
Total return (dividends reinvested) (XRTX)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -66.6% | -99.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -66.7% | -74.0% |
| Volatility (annualized) | 108.0% | 146.7% |
| Max drawdown | -74.4% (Oct 2025→Oct 2026) | -99.9% (Nov 2021→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:49 UTC)
| Price | USD 1.42 |
|---|---|
| Change | ▼ 8.97% (down) |
| Previous Close | USD 1.56 |
| Open | USD 1.53 |
| Day Range | USD 1.41 – 1.54 |
| 52-Week Range | USD 1.36 – 7.05 |
| Volume | 91,997 shares |
| Market Cap | $2.58M |
| Exchange | NCM |
Technical Analysis (XRTX)
Nexqual's technical model rates XRTX "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.07 (neutral) |
| vs SMA50 | Below (USD 1.97) |
| MACD | -0.12 (negative) |
Earnings (XRTX)
| Next Earnings Date | 2026-11-12 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.45 vs est -1.58 ▲ beat |
| 2025-09-30 | USD -1.02 vs est -1.58 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Financials & Fundamentals (XRTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -99.24% |
| Current Ratio | 3.59 |
| Total Cash | $994,045 |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Ownership (XRTX)
| Insider Ownership | +1.53% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 1.82M |
| Float | 1.79M |
| Short % of Float | +3.44% |
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt